Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer

Neoplasia

Volumn 12, Issue 11, 2010, Pages 941-945

  Witteveen, Petronella O ^a   Van der Mijn, Koen J C ^a   Los, Maartje ^b   Kronemeijer, Roelien H ^a   Groenewegen, Gerard ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; DOXORUBICIN; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; RHINITIS; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH;

EID: 78449253990     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10582     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007). Cancer statistics. CA Cancer J Clin 57, 43-66.
2. du Bois A, Quinn M, Thigpen T, Vermorken J, Vall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, et al. (2005). 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol 16(suppl 8), viii7-viii12.
3. Bristow RE and Chi DS (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103, 1070-1076.
4. Lorusso D, Ferrandina G, Lo Voi R, Fagotti A, and Scambia G (2004). Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer. J Chemother 16, 98-103.
5. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, and Rose PG (2005). Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96, 10-18.
6. Grant K, Loizidou M, and Taylor I (2003). Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88, 163-166.
7. Bagnato A, Salani D, Di CV, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, and Natali PG (1999). Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59, 720-727.
8. Rosano L, Spinella F, Salani D, Di CV, Venuti A, Nicotra MR, Natali PG, and Bagnato A (2003). Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63, 2447-2453.
9. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, et al. (2002). Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20, 2171-2180.
10. Rosano L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, and Bagnato A (2006). Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Biol Med 231, 1128-1131.
11. Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Hunerickhouse RA, Isaacson JD, Carr RA, and Voest EE (2003). Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9, 2965-2972.
12. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Hunerickhouse R, Andre AK, Wang Q, Carr RA, and Ratian MJ (2004). Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 10, 4406-4411.
13. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, and Nelson JB (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 110, 1959-1966.
14. Carducci MA, Padley RJ, and Breul J (2003). Effect of endothelin-A blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21, 679-689.
15. Chiappori AA, Haura E, and Rodriguez FA (2008). Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 14, 1464-1469.
16. Kefford R, Beith JM, and van Hazel GA (2007). A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 25, 247-252.
17. Gegan EA and Schneiderman MA (1982). Experimental design of clinical trials. In Cancer Medicine. JF Holland and E Frei III (Eds). Lea and Febiger, Philadelphia, PA. pp. 531-553.
18. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, and Sharpington T (2000). Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18, 3093-3100.
19. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, and Lacave AJ (2001). Recurrent epithelial ovarian carcinoma: a randomized phase II study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19, 3312-3322.
20. Ferrandina G, Ludovisi M, Lorusso D, Pgnata S, Breda E, Savarese A, DelMedica P, Scaltriti L, Katsaros D, Priolo D, et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin progressive or recurrent ovarian cancer. J Clin Oncol 26, 890-896.
21. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, and Toner GC (1996). Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63, 89-93.
22. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, and Kayitalire L (1998). A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 19, 1343-1345.
23. Rose PG, Blessing JA, Mayer AR, and Homesly D(1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic Oncology Group Study. J Clin Oncol 16, 405-410.
24. Bookman MA, Halmstrom H, Bolis G, Gordon A, Lissone A, Krebs JB, and Fields SZ (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16, 3345-3352.